Huma and Merck KGaA Collaborate on Digital Solutions for Cancer Care

Huma Therapeutics and Merck KGaA, Darmstadt, Germany, have announced a partnership to develop a digital solution that aims to help cancer patients better understand and manage their conditions and treatment.

The Cross-Indication Disease Management Platform will be made available to patients being treated with Merck KGaA, Darmstadt, Germany’s cancer therapies.

Set for initial launch in 2024, the preliminary direct-to-patient solution will support urothelial carcinoma patients in the UK.

Utilising Huma’s disease-agnostic Software as a Medical Device (SaMD) technology platform, the first of its kind to achieve both EU MDR Class IIb regulation and FDA Class 2 510(k) clearance, the collaboration between Huma and Merck KGaA, Darmstadt, Germany aspires to (with local specifications):

  • Increase patient understanding of their condition and treatment protocols, encouraging adherence to prescribed treatment
  • Encourage discussions between patients and their care team
  • Deliver timely educational content
  • Support connections between patients and caregivers, fostering a supportive community network

To view the source version, please click HERE.

en_GBEnglish (UK)